Skip to content
OpenCapital
Get started

X4 Pharmaceuticals XFOR Q4 2024 Annual earnings

Reported March 25, 2025 · Before market open

Revenue$1.4MMiss by $800.2K
EPS-$6.01Miss by $0.90
Revenue estimate$2.2M
EPS estimate-$5.11

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$2.4M
EPS estimate-$0.19

Versus estimates

Revenue

Q1 2026$2.5MMiss by $731.0KQ4 2025$2.6MBeat by $835.0KQ3 2025$1.8MBeat by $32.0KQ2 2025$2.0MMiss by $253.4KQ1 2025$28.8MBeat by $26.9M
Q4 2024$1.4MMiss by $800.2K

Diluted EPS

Q1 2026-$0.16Beat by $0.04Q4 2025-$0.22Beat by $0.14Q3 2025-$0.69Beat by $0.10Q2 2025-$3.47Beat by $1.06Q1 2025$0.04Beat by $4.17
Q4 2024-$6.01Miss by $0.90

Ask the moment X4 Pharmaceuticals reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did X4 Pharmaceuticals report Q4 2024 earnings?
X4 Pharmaceuticals (XFOR) reported Q4 2024 earnings on March 25, 2025 before market open.
What were X4 Pharmaceuticals's Q4 2024 revenue and EPS?
X4 Pharmaceuticals reported revenue of $1.4M and eps of $-6.01 for Q4 2024.
Did X4 Pharmaceuticals beat estimates in Q4 2024?
Revenue missed the consensus estimate of $2.2M by $800.2K. EPS missed the consensus estimate of $-5.11 by $0.90.
Where can I find X4 Pharmaceuticals's Q4 2024 SEC filings?
You can read the 10-K periodic report (0001628280-25-014805) directly on SEC EDGAR. The filing index links above go to sec.gov.